article
Clinical trial disruptions: is it all down to COVID-19?
This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.
List view / Grid view
Industry Insight
news
Novo Nordisk set to acquire Emisphere for $1.8 billion
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
news
FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidate
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
news
COVID-19 therapeutics to rely on large-scale biomanufacturing reactors, report says
A new report has found that if COVID-19 biologics are approved, it could apply pressure to the global biomanufacturing capacity.
news
Lack of skill and talent biggest challenge to digital transformation in pharma
A report has found that the biggest hurdle for digital transformation in pharma is a lack of specific skills and talents, followed by organisational silos.
news
Use of paper tube-pouch could reduce plastic in pharma packaging
According to the developers of a new paper tube-pouch, its design could reduce plastic use by up to 65 percent in pharma packaging.
news
US pharma industry responds to American election result
PhRMA has released a statement following the announcement that Joe Biden will be the next President of the US.
news
Recipients of Suffrage Science awards announced
The Suffrage Science awards recognise the efforts of 22 leading women in life sciences and mathematics & computing.
news
Slow CMO revenue growth could impact US
Dose contract manufacturing organisations (CMOs) had slow revenue growth in 2019, a trend continuing into 2020 that could impact the US.
news
GSK sets goals of net zero impact on environment by 2030
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.
news
Pharma M&A activity up 17 percent year-on-year in H1 of 2020
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
article
Has COVID-19 changed public perception of pharmaceutical companies?
EPR’s Hannah Balfour explores pharma’s reputation prior to the pandemic and the impact of COVID-19, highlighting areas which pharma could focus on to improve consumer relations and drive public engagement and trust.
article
Improving fungal ID options
This article explores a novel method for fungal identification. A case study is presented which showed this method was superior to the reference method with increased identification rates and lower misidentification.
![Phone with regeneron logo on it in front of blurred laboratory background [Credit: adrianosiker.com/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Regeneron-300x278.jpg)
![Phone with regeneron logo on it in front of blurred laboratory background [Credit: adrianosiker.com/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Regeneron-scaled-e1604327714270.jpg)
news
Regeneron named top biopharma company to work for
According to Regeneron, it has placed either first or second in the same ranking for the past ten years, making it the most highly ranked company of the decade.
article
Scaling up production capacity when the world is waiting
As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.
